Inventor
YIFAN ZHAI
Inventor
CN
Overview
Patents· 36 as inventor
Public. Assignee & technology derived from the patent record. Each patent links to its LexDana page.
A61Kprimary
A61KPreparations for medical, dental or toiletry purposes26%
A61PSpecific therapeutic activity of chemical compounds or medicinal preparations26%
C07DHeterocyclic compounds13%
LOC0612%
C07KPeptides5%
LOC255%
A47CChairs1%
B25HWorkshop equipment, e.g. for marking-out work1%
B65DContainers for storage or transport of articles or materials, e.g. bags, barrels, bottles, boxes, cans, cartons, crates, drums, jars, tanks, hoppers, forwarding containers1%
C07BGeneral methods of organic chemistry1%
PatentTitleYear
12,584,313Floor and wallboard connecting structure for shed202612,564,270Bushing and bed frame202612,544,370Methods for cancer therapy202612,514,863Pharmaceutical combination and use thereof2026D1097427Storage shed202512,370,197Combination product of a Bcl-2/Bcl-xL inhibitor and a chemotherapeutic agent and use thereof in the prevention and/or treatment of diseases202512,343,352N-(phenylsulfonyl)benzamides and related compounds as Bcl-2 inhibitors2025D1082050Storage shed202512,304,692Storage box202512,287,338Method and compositions for predicting anti-cancer efficacy of compounds targeting apoptosis pathway202512,268,665Combination of immunotherapies with MDM2 inhibitors2025D1069171Storage shed202512,233,047Pharmaceutical combination and use thereof2025D1059912Cabinet2025D1058193Combined storage box and seat202512,194,024Pharmaceutical composition of MDM2 inhibitor and use thereof for preventing and/or treating disease202512,186,304Method for treating cancer by combination of IAP inhibitor and modulator of immune checkpoint molecule2025D1054590Outdoor screen2024D1053560Storage box2024D1048773Storage box2024D1047433Storage box2024D1044350Cabinet202412,083,136Combination of BCL-2/BCL-XL inhibitors and chemotherapeutic agent and use thereof2024D1021440Rattan chair2024D1020279Gaming chair2024D1012494Storage box202411,850,239MDM2 inhibitor and a platinum compound for cancer treatment202311,554,127Synergistic antitumor effect of Bcl-2 inhibitor combined with rituximab and/or bendamustine or Bcl-2 inhibitor combined with CHOP202311,491,168Combination of Bcl-2/Bcl-xL inhibitors and chemotherapeutic agent and use thereof202211,491,167Combination product of Bcl-2 inhibitor and chemotherapeutic agent and use thereof in the prevention and/or treatment of diseases202211,478,477Method for treating cancer by combination of FAK/ALK/ROS1 inhibitor and EGFR inhibitor202211,478,469Combination product of BCL-2 inhibitor and MDM2 inhibitor and use thereof in the prevention and/or treatment of diseases202211,478,470Combination product of Bcl-2 inhibitor or Bcl-2/Bcl-xL dual inhibitor and BTK inhibitor and use thereof in the prevention and/or treatment of diseases202211,452,716Pharmaceutical composition and use thereof202211,395,815Compound for treating osteoarthritis202211,298,339Bisdiazabicyclo compound for treatment and/or prevention of hepatitis virus-related diseases or disorders2022Career & activity timeline
Assembled from patent assignee/location history and declaration credentials.
2022–2026Patents assigned to ASCENTAGE PHARMA SUZHOU CO LTD (19)· patent assignee history
2022–2026Patents assigned to ASCENTAGE PHARMA GROUP CORP LTD (11)· patent assignee history
2022Patents assigned to HEALTHQUEST PHARMA INC (1)· patent assignee history
2022–2026Based in CN· patent location history
2024–2026Patents assigned to JINGNING MEIGE TECH SERVICE CO LTD (15)· patent assignee history
2025Patents assigned to GUANGZHOU HEALTHQUEST PHARMA CO LTD (1)· patent assignee history
Inventor activity
Assignee and location history derived from the patent record.
Assignees
| Assignee | Patents | Span |
|---|---|---|
| ASCENTAGE PHARMA SUZHOU CO LTD | 19 | 2022–2026 |
| JINGNING MEIGE TECH SERVICE CO LTD | 15 | 2024–2026 |
| ASCENTAGE PHARMA GROUP CORP LTD | 11 | 2022–2026 |
| GUANGZHOU HEALTHQUEST PHARMA CO LTD | 1 | 2025 |
| HEALTHQUEST PHARMA INC | 1 | 2022 |
Locations
| Location | Patents | Span |
|---|---|---|
| CN | 36 | 2022–2026 |